Open-mkt buys · 90d
$24.1K
3 trades · 1 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$24.1K
Insiders on file
22
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Lerner Neil | SVP, CAO | 9 | $80.8K | $0 | 2026-10-01 |
| Anderman Jonathan | Sr VP, Gen Counsel & Corp Sec | 7 | $78.0K | $0 | 2026-04-29 |
| Schuetz Thomas J. | President of R&D | 40 | $1.17M | $0 | 2026-02-08 |
| Prasad Arjun | Chief Commercial Officer | 1 | $0 | $0 | 2026-01-02 |
| Boylan James P | Director | 3 | $0 | $0 | 2026-01-02 |
| Ferneau Philip | Director | 5 | $0 | $0 | 2026-01-02 |
| Sirard Cynthia | Chief Medical Officer | 1 | $0 | $0 | 2026-01-02 |
| Shin Barry | CFO | 5 | $0 | $0 | 2026-01-02 |
| Chiniara Ellen | Director | 5 | $0 | $0 | 2026-01-02 |
| GORDON CARL L | Director, 10% Owner | 15 | $20.66M | $5.68M | 2026-01-02 |
| GRAY MARY ANN | Director | 5 | $0 | $0 | 2026-01-02 |
| LINDAHL RICHARD S | Director | 4 | $0 | $0 | 2026-01-02 |
| OrbiMed Capital GP VI LLC | Director, 10% Owner | 1 | $0 | $5.68M | 2025-04-09 |
| Bisker-Leib Vered | President & COO | 15 | $0 | $200.7K | 2024-02-08 |
| WURZER DAVID M | Director | 1 | $0 | $0 | 2023-02-08 |
| ORBIMED ADVISORS LLC | Director, 10% Owner | 4 | $1.71M | $0 | 2022-11-08 |
| OrbiMed Capital GP V LLC | Director, 10% Owner | 3 | $197.3K | $0 | 2022-05-10 |
| Kalled Susan | Chief Scientific Officer | 2 | $0 | $0 | 2022-02-18 |
| Kaplan Brett | Director | 1 | $0 | $0 | 2022-02-18 |
| SQUINTO STEPHEN P | Director | 1 | $0 | $0 | 2022-02-18 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 2 | $18.75M | $0 | 2021-11-04 |
| Toledano Miranda Jayne | Director | 2 | $0 | $0 | 2021-06-25 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer | P Buy | 2026-10-01 | 2026-10-02 | 20,000 | $0.92 | $18.4K | 420,000 | SEC↗ |
| Lerner Neil | Chief Accounting Officer | P Buy | 2026-09-24 | 2026-09-25 | 2,500 | $1.14 | $2.8K | 400,000 | SEC↗ |
| Lerner Neil | Chief Accounting Officer | P Buy | 2026-09-24 | 2026-09-25 | 2,500 | $1.14 | $2.9K | 400,000 | SEC↗ |
| Lerner Neil | Chief Accounting Officer | A Award | 2026-04-29 | 2026-04-29 | 15,000 | $1.89 | $28.4K | 397,500 | SEC↗ |
| Anderman Jonathan | General Counsel | A Award | 2026-04-29 | 2026-04-29 | 25,000 | $1.89 | $47.3K | 196,000 | SEC↗ |
| Anderman Jonathan | General Counsel | P Buy | 2026-04-29 | 2026-04-30 | 25,000 | $1.89 | $47.3K | 196,000 | SEC↗ |
| Lerner Neil | Chief Accounting Officer | P Buy | 2026-04-29 | 2026-04-30 | 15,000 | $1.89 | $28.4K | 397,500 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | F Tax w/h | 2026-02-08 | 2026-02-10 | 36,687 | $6.52 | $239.2K | 6,603,336 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | F Tax w/h | 2026-01-09 | 2026-01-12 | 46,777 | $5.35 | $250.3K | 6,640,023 | SEC↗ |
| Anderman Jonathan | General Counsel | A Award deriv | 2026-01-02 | 2026-01-05 | 720,000 | — | $0 | 720,000 | SEC↗ |
| Ferneau Philip | Director | A Award deriv | 2026-01-02 | 2026-01-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| GORDON CARL L | Director | A Award deriv | 2026-01-02 | 2026-01-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Boylan James P | Director | A Award deriv | 2026-01-02 | 2026-01-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| GRAY MARY ANN | Director | A Award deriv | 2026-01-02 | 2026-01-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Lerner Neil | Chief Accounting Officer | A Award deriv | 2026-01-02 | 2026-01-05 | 435,000 | — | $0 | 435,000 | SEC↗ |
| Chiniara Ellen | Director | A Award deriv | 2026-01-02 | 2026-01-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| LINDAHL RICHARD S | Director | A Award deriv | 2026-01-02 | 2026-01-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Prasad Arjun | Chief Commercial Officer | A Award deriv | 2026-01-02 | 2026-01-05 | 1,000,000 | — | $0 | 1,000,000 | SEC↗ |
| Schuetz Thomas J. | CEO | A Award deriv | 2026-01-02 | 2026-01-05 | 2,000,000 | — | $0 | 2,000,000 | SEC↗ |
| Sirard Cynthia | Chief Medical Officer | A Award deriv | 2026-01-02 | 2026-01-05 | 1,000,000 | — | $0 | 1,000,000 | SEC↗ |
| Shin Barry | CFO | A Award deriv | 2026-01-02 | 2026-01-05 | 670,000 | — | $0 | 670,000 | SEC↗ |
| Anderman Jonathan | General Counsel | A Award | 2026-01-02 | 2026-01-05 | 150,000 | $5.17 | $775.5K | 171,000 | SEC↗ |
| Lerner Neil | Chief Accounting Officer | A Award | 2026-01-02 | 2026-01-05 | 62,500 | $5.17 | $323.1K | 382,500 | SEC↗ |
| Schuetz Thomas J. | CEO | A Award | 2026-01-02 | 2026-01-05 | 250,000 | $5.17 | $1.29M | 6,686,800 | SEC↗ |
| Shin Barry | CFO | A Award | 2026-01-02 | 2026-01-05 | 125,000 | $5.17 | $646.3K | 525,000 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | F Tax w/h | 2025-11-16 | 2025-11-18 | 44,025 | $4.83 | $212.6K | 6,436,800 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2025-05-27 | 2025-05-27 | 10,000 | $2.11 | $21.1K | 6,480,825 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director, 10% Owner | S Sale | 2025-04-09 | 2025-04-11 | 3,571,428 | $1.59 | $5.68M | 0 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | S Sale | 2025-04-09 | 2025-04-11 | 3,571,428 | $1.59 | $5.68M | 0 | SEC↗ |
| Lerner Neil | CHIEF ACCOUNTING OFFICER | P Buy | 2025-04-07 | 2025-04-08 | 20,000 | $1.42 | $28.4K | 320,000 | SEC↗ |
| Anderman Jonathan | Gen Counsel & Corporate Sec | P Buy | 2025-04-07 | 2025-04-08 | 20,000 | $1.54 | $30.8K | 21,000 | SEC↗ |
| Boylan James P | Director | A Award deriv | 2025-02-11 | 2025-02-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | A Award deriv | 2025-02-11 | 2025-02-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Anderman Jonathan | Sr VP, Gen Counsel & Corp Se | A Award deriv | 2025-02-11 | 2025-02-13 | 280,000 | — | $0 | 280,000 | SEC↗ |
| Chiniara Ellen | Director | A Award deriv | 2025-02-11 | 2025-02-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Ferneau Philip | Director | A Award deriv | 2025-02-11 | 2025-02-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| GRAY MARY ANN | Director | A Award deriv | 2025-02-11 | 2025-02-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Lerner Neil | SVP, CAO | A Award deriv | 2025-02-11 | 2025-02-13 | 200,000 | — | $0 | 200,000 | SEC↗ |
| LINDAHL RICHARD S | Director | A Award deriv | 2025-02-11 | 2025-02-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | A Award deriv | 2025-02-11 | 2025-02-13 | 1,500,000 | — | $0 | 1,500,000 | SEC↗ |
| Shin Barry | CFO | A Award deriv | 2025-02-11 | 2025-02-13 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Schuetz Thomas J. | CEO | F Tax w/h | 2025-02-08 | 2025-02-11 | 41,687 | $3.50 | $145.9K | 6,470,825 | SEC↗ |
| Schuetz Thomas J. | CEO | F Tax w/h | 2025-01-09 | 2025-01-13 | 58,054 | $1.86 | $108.0K | 6,512,512 | SEC↗ |
| Shin Barry | CFO | A Award deriv | 2024-12-09 | 2024-12-10 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Shin Barry | CFO | A Award | 2024-12-09 | 2024-12-10 | 400,000 | $1.65 | $660.0K | 400,000 | SEC↗ |
| Anderman Jonathan | Sr VP, Gen Counsel & Corp Se | A Award deriv | 2024-08-13 | 2024-08-14 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Boylan James P | Director | A Award deriv | 2024-03-08 | 2024-03-11 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Ferneau Philip | Director | A Award deriv | 2024-02-09 | 2024-02-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Chiniara Ellen | Director | A Award deriv | 2024-02-09 | 2024-02-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | A Award deriv | 2024-02-09 | 2024-02-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| LINDAHL RICHARD S | Director | A Award deriv | 2024-02-09 | 2024-02-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| GRAY MARY ANN | Director | A Award deriv | 2024-02-09 | 2024-02-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Schuetz Thomas J. | PRESIDENT | F Tax w/h | 2024-02-08 | 2024-02-09 | 44,782 | $1.45 | $64.9K | 6,570,566 | SEC↗ |
| Bisker-Leib Vered | CHIEF EXECUTIVE OFFICER | F Tax w/h | 2024-02-08 | 2024-02-09 | 49,198 | $1.45 | $71.3K | 3,124,426 | SEC↗ |
| Schuetz Thomas J. | President of R&D | A Award deriv | 2024-01-09 | 2024-01-10 | 637,500 | — | $0 | 637,500 | SEC↗ |
| Bisker-Leib Vered | Chief Executive Officer | A Award deriv | 2024-01-09 | 2024-01-10 | 1,753,125 | — | $0 | 1,753,125 | SEC↗ |
| Schuetz Thomas J. | President of R&D | A Award | 2024-01-09 | 2024-01-10 | 637,500 | $1.93 | $1.23M | 6,615,348 | SEC↗ |
| Bisker-Leib Vered | Chief Executive Officer | A Award | 2024-01-09 | 2024-01-10 | 1,753,125 | $1.93 | $3.38M | 3,173,624 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | F Tax w/h | 2023-11-17 | 2023-11-21 | 44,025 | $1.50 | $66.0K | 5,977,848 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | F Tax w/h | 2023-11-17 | 2023-11-21 | 64,415 | $1.50 | $96.6K | 1,420,499 | SEC↗ |
| LINDAHL RICHARD S | Director | A Award deriv | 2023-04-21 | 2023-04-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2023-03-10 | 2023-03-10 | 10,000 | $3.37 | $33.7K | 6,021,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2023-02-27 | 2023-02-27 | 20,000 | $3.98 | $79.6K | 6,011,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2023-02-15 | 2023-02-15 | 20,000 | $3.86 | $77.2K | 5,991,873 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | A Award deriv | 2023-02-08 | 2023-02-09 | 600,000 | — | $0 | 600,000 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | A Award deriv | 2023-02-08 | 2023-02-09 | 700,000 | — | $0 | 700,000 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | A Award deriv | 2023-02-08 | 2023-02-09 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Ferneau Philip | Director | A Award deriv | 2023-02-08 | 2023-02-09 | 50,000 | — | $0 | 50,000 | SEC↗ |
| GRAY MARY ANN | Director | A Award deriv | 2023-02-08 | 2023-02-09 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Chiniara Ellen | Director | A Award deriv | 2023-02-08 | 2023-02-09 | 40,000 | — | $0 | 40,000 | SEC↗ |
| WURZER DAVID M | Director | A Award deriv | 2023-02-08 | 2023-02-10 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | A Award | 2023-02-08 | 2023-02-09 | 400,000 | — | $0 | 1,484,914 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | A Award | 2023-02-08 | 2023-02-09 | 500,000 | — | $0 | 5,971,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2023-01-31 | 2023-01-31 | 20,000 | $4.05 | $81.0K | 5,471,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2023-01-24 | 2023-01-24 | 20,000 | $4.19 | $83.8K | 5,451,873 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | S Sale | 2022-11-25 | 2022-11-25 | 2 | $4.36 | $9 | 1,060,414 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | S Sale | 2022-11-23 | 2022-11-25 | 9,569 | $4.30 | $41.1K | 1,060,416 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | S Sale | 2022-11-22 | 2022-11-25 | 14,929 | $4.19 | $62.6K | 1,069,985 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | S Sale | 2022-11-21 | 2022-11-22 | 16,035 | $4.34 | $69.6K | 1,084,914 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | S Sale | 2022-11-18 | 2022-11-22 | 6,226 | $4.40 | $27.4K | 1,107,175 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-11-08 | 2022-11-10 | 402,000 | $3.21 | $1.29M | 15,219,994 | SEC↗ |
| ORBIMED ADVISORS LLC | Director, 10% Owner | P Buy | 2022-11-08 | 2022-11-10 | 402,000 | $3.21 | $1.29M | 15,219,994 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-09-28 | 2022-09-28 | 10,000 | $2.32 | $23.2K | 5,431,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-09-26 | 2022-09-27 | 15,000 | $2.27 | $34.0K | 5,421,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-09-07 | 2022-09-08 | 15,000 | $3.03 | $45.5K | 5,406,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-09-01 | 2022-09-01 | 15,000 | $2.83 | $42.5K | 5,391,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-08-17 | 2022-08-17 | 15,000 | $3.05 | $45.8K | 5,376,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-08-10 | 2022-08-10 | 15,000 | $2.64 | $39.6K | 5,361,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-08-01 | 2022-08-02 | 15,000 | $2.58 | $38.7K | 5,346,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-06-21 | 2022-06-21 | 20,000 | $2.80 | $56.0K | 5,331,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-06-16 | 2022-06-17 | 20,000 | $2.34 | $46.8K | 5,311,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-06-13 | 2022-06-13 | 30,000 | $2.29 | $68.7K | 5,291,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-06-06 | 2022-06-07 | 30,000 | $2.83 | $84.9K | 5,261,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-06-01 | 2022-06-01 | 20,000 | $3.03 | $60.6K | 5,231,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-05-26 | 2022-05-26 | 20,000 | $3.04 | $60.8K | 5,211,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-05-23 | 2022-05-24 | 18,355 | $2.72 | $49.9K | 5,191,873 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-05-17 | 2022-05-17 | 20,215 | $2.47 | $49.9K | 5,173,518 | SEC↗ |
| ORBIMED ADVISORS LLC | Director, 10% Owner | P Buy | 2022-05-13 | 2022-05-13 | 30,722 | $2.49 | $76.5K | 14,817,994 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-05-13 | 2022-05-13 | 30,722 | $2.49 | $76.5K | 14,817,994 | SEC↗ |
| ORBIMED ADVISORS LLC | Director, 10% Owner | P Buy | 2022-05-12 | 2022-05-13 | 97,094 | $2.35 | $228.2K | 14,787,272 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-05-12 | 2022-05-13 | 97,094 | $2.35 | $228.2K | 14,787,272 | SEC↗ |
| ORBIMED ADVISORS LLC | Director, 10% Owner | P Buy | 2022-05-11 | 2022-05-13 | 64,700 | $1.79 | $115.8K | 14,690,178 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-05-11 | 2022-05-13 | 64,700 | $1.79 | $115.8K | 14,690,178 | SEC↗ |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | P Buy | 2022-05-10 | 2022-05-10 | 27,836 | $1.80 | $50.1K | 5,153,303 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-05-10 | 2022-05-10 | 24,447 | $1.60 | $39.1K | 14,625,478 | SEC↗ |
| OrbiMed Capital GP V LLC | Director, 10% Owner | P Buy | 2022-05-10 | 2022-05-10 | 24,447 | $1.60 | $39.1K | 14,625,478 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-05-09 | 2022-05-10 | 90,712 | $1.56 | $141.5K | 14,601,031 | SEC↗ |
| OrbiMed Capital GP V LLC | Director, 10% Owner | P Buy | 2022-05-09 | 2022-05-10 | 90,712 | $1.56 | $141.5K | 14,601,031 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2022-05-06 | 2022-05-10 | 10,200 | $1.63 | $16.6K | 14,510,319 | SEC↗ |
| OrbiMed Capital GP V LLC | Director, 10% Owner | P Buy | 2022-05-06 | 2022-05-10 | 10,200 | $1.63 | $16.6K | 14,510,319 | SEC↗ |
| Chiniara Ellen | Director | A Award deriv | 2022-04-26 | 2022-04-28 | 45,000 | — | $0 | 45,000 | SEC↗ |
| GRAY MARY ANN | Director | A Award deriv | 2022-04-26 | 2022-04-28 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Schuetz Thomas J. | Chief Executive Officer | A Award deriv | 2022-02-18 | 2022-02-23 | 700,000 | — | $0 | 700,000 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | A Award deriv | 2022-02-18 | 2022-02-23 | 500,000 | — | $0 | 500,000 | SEC↗ |
| Kalled Susan | Chief Scientific Officer | A Award deriv | 2022-02-18 | 2022-02-23 | 60,000 | — | $0 | 60,000 | SEC↗ |
| SQUINTO STEPHEN P | Director | A Award deriv | 2022-02-18 | 2022-02-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Kaplan Brett | Director | A Award deriv | 2022-02-18 | 2022-02-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | A Award deriv | 2022-02-18 | 2022-02-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Ferneau Philip | Director | A Award deriv | 2022-02-18 | 2022-02-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Kalled Susan | Chief Scientific Officer | A Award deriv | 2022-02-17 | 2022-02-18 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | A Award deriv | 2022-02-17 | 2022-02-18 | 500,000 | — | $0 | 500,000 | SEC↗ |
| Schuetz Thomas J. | Chief Executive Officer | A Award deriv | 2022-02-17 | 2022-02-18 | 700,000 | — | $0 | 700,000 | SEC↗ |
| Bisker-Leib Vered | Chief Operating Officer | A Award | 2021-11-16 | 2021-11-18 | 600,000 | — | $0 | 1,113,401 | SEC↗ |
| OrbiMed Genesis GP LLC | Director, 10% Owner | P Buy | 2021-11-04 | 2021-11-08 | 3,571,428 | $3.50 | $12.50M | 3,571,428 | SEC↗ |
| OrbiMed Genesis GP LLC | Director, 10% Owner | P Buy | 2021-11-04 | 2021-11-08 | 1,785,715 | $3.50 | $6.25M | 14,500,119 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2021-11-04 | 2021-11-08 | 3,571,428 | $3.50 | $12.50M | 3,571,428 | SEC↗ |
| GORDON CARL L | Director, 10% Owner | P Buy | 2021-11-04 | 2021-11-08 | 1,785,715 | $3.50 | $6.25M | 14,500,119 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award deriv | 2021-06-25 | 2021-06-29 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Toledano Miranda Jayne | Director | J Other | 2021-06-25 | 2021-06-29 | 1,791,549 | — | $0 | 1,791,549 | SEC↗ |
| Bisker-Leib Vered | President & COO | A Award deriv | 2021-02-09 | 2021-03-01 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Schuetz Thomas J. | Chief Executive Officer | A Award deriv | 2021-02-09 | 2021-03-01 | 700,000 | — | $0 | 700,000 | SEC↗ |
| Schuetz Thomas J. | Chief Executive Officer | A Award deriv | 2020-12-22 | 2020-12-23 | 250,000 | — | $0 | 250,000 | SEC↗ |